Streetbeat News

MDGL

Madrigal Pharmaceuticals, Inc.

https://www.madrigalpharma.com

Industry

Biotechnology

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Open

303.29

Mkt cap

6.3B

Volume

934K

High

303.29

P/E Ratio

-11.53

52-wk high

368.29

Low

272.72

Div yield

N/A

52-wk low

166.00

Citigroup analyst David Lebowitz initiates coverage on Madrigal Pharmaceuticals (MDGL) with a Buy rating and sets a price target of $382.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 10:22 am

Oppenheimer analyst Jay Olson has maintained an Outperform rating on Madrigal Pharmaceuticals (MDGL) and increased the price target from $300 to $320.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 4:15 pm

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported Q4 earnings with an EPS of $-5.68, missing estimates by -8.0%. Revenue remained unchanged from the previous year. Despite missing EPS estimates last quarter followed by a share price increase, this quarter's performance may concern investors.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 2:20 pm

Madrigal Pharmaceuticals has announced the appointment of Mardi Dier as the company's Chief Financial Officer (CFO).

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:12 pm

Madrigal Pharmaceuticals reported a Q4 EPS loss of $(5.68), missing the consensus estimate of $(5.28) by 7.58%. This represents a 14.06% increase in losses compared to the same period last year. The company also reported having $634M in cash, cash equivalents, and marketable securities.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:11 pm

B. Riley Securities analyst Mayank Mamtani downgraded Madrigal Pharmaceuticals (MDGL) from Neutral to Sell and reduced the price target from $204 to $155. This adjustment reflects a more bearish outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 2:17 pm

B. Riley Securities analyst Mayank Mamtani downgrades Madrigal Pharmaceuticals (MDGL) from Neutral to Sell and sets a price target of $155.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 4:33 pm

JMP Securities analyst Jonathan Wolleben has reiterated a 'Market Outperform' rating on Madrigal Pharmaceuticals (MDGL) and maintained a price target of $347.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 5:38 pm

JMP Securities analyst Jonathan Wolleben has reiterated a 'Market Outperform' rating on Madrigal Pharmaceuticals (MDGL) and maintained a price target of $347.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 7:46 pm

In Tuesday's pre-market session, several healthcare stocks showed significant movement. Exicure (XCUR) led the gainers with a 55.5% increase, while Madrigal Pharmaceuticals (MDGL) experienced the largest drop among the losers, declining by 15.9%. Other notable movers included InVivo Therapeutics (NVIV), Helius Medical Tech (HSDT), and Akero Therapeutics (AKRO). The movements reflect varying market valuations and investor reactions to company-specific news or broader sector trends.

Portfolio Pulse from Benzinga Insights

February 06, 2024 | 1:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.